DUBLIN, March 26, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/fp9n2f/large_volume) has announced the addition of the "Large Volume Injection Devices for Self-Administration" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Biological drugs continue to increase in terms of the absolute number of new approved drugs and as a percent of all approved drugs. In two of the largest (in terms of revenue) and fastest growing therapeutic segments - autoimmune diseases and oncology - the majority of drugs consist of monoclonal antibodies (mAbs). Therapeutic drugs consisting of proteins and peptides present unique drug packaging and delivery challenges.
Often the dosing volume required to achieve a therapeutic effect requires the drug to be delivered via infusion, resulting in logistical, cost and safety issues. Drug developers and their delivery technology partners are attempting to address this limitation. The development of injectors capable of delivering drug volumes of 2 mL or higher subcutaneously is one promising method. This report examines this new class of devices and analyzes their potential impact on biological drug delivery.
HIGHLIGHTS
WHAT YOU WILL LEARN
Key Topics Covered:
Executive Summary
Large Volume Injectables Market Dynamics
The Trend toward Patient Self-Administration
Drug Delivery Device Evolution
Enabling Technology
Drug Development Trends
Large Volume Wearable Injectors - Design Factors
Volumes and Viscosities
Flow Rates
Dosing Regimens
Patient Variability
Primary Packaging
Injection Methodology
Patient Interface
Large Volume Delivery Devices
Unbranded Injector (Enable Injections)
Microinfusor (BD Medical)
Unbranded Injector (Roche)
OmniPod (Insulet)
SmartDose (West Pharmaceuticals)
SensePatch FD/SD (Sensile Medical)
Unbranded Injector (SteadyMed)
Precision Therapy/Flex Therapy (Unilife)
Large Volume Injection Devices - Near-Term Products
Herceptin SC (Roche/Halozyme)
Furosemide (scPharmaceuticals/Sensile Medical)
GnRH (Ferring/Insulet)
Prostacyclin (SteadyMed)
Therapeutic Market Segment Analysis & Forecasts
Inflammatory Autoimmune Diseases
Blood Disorders
Cardiovascular
Neurology
Oncology
Metabolic Diseases
Multiple Sclerosis
Reproductive Health
Upper Respiratory Diseases
Market Factors
Self-Administration and Patient Compliance
Regulatory Guidance and Product Approvals
Drug Product Differentiation/Marketability
Company Profiles
For more information visit http://www.researchandmarkets.com/research/fp9n2f/large_volume
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article